Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [2] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [2] - Lucid's EsoGuard® Esophageal DNA Test is the first and only commercially available tool aimed at preventing cancer through early detection of esophageal precancer [2] Compliance Notification - Lucid Diagnostics received a written notification from Nasdaq indicating eligibility for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement [4] - The company must maintain a closing bid price of at least$1.00 per share for a minimum of ten consecutive business days during the extension period [1][4] - The deadline to meet this requirement is June 16, 2025 [4]